This study is not accepting new patients

Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis

a study on Leishmaniasis

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California
Dates
study start
Principal Investigator
by Brian Schwartz
Headshot of Brian Schwartz
Brian Schwartz

Description

Summary

Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).

Keywords

Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous, New World Cutaneous or Mucocutaneous Leishmaniasis, Leishmaniasis, Cutaneous Leishmaniasis, Mucocutaneous Leishmaniasis, Antimony Sodium Gluconate, sodium stibogluconate (Pentostam)

Eligibility

You can join if…

Open to people ages 18 years and up

- Biopsy proven new world cutaneous or mucocutaneous leishmania

You CAN'T join if...

  • Prolonged QT
  • Liver disease
  • Pancreatitis

Location

  • University of CA at San Francisco Hospitals and Clinics not accepting new patients
    San Francisco California 94143 United States

Lead Scientist at UCSF

  • Brian Schwartz
    Brian Schwartz is a physician specializing in the treatment of infectious diseases, specifically the diagnosis, treatment, and prevention of infections in immunocompromised patients. He serves as the Associate Chair of Education for the Department of Medicine.

Details

Status
not accepting new patients
Start Date
Sponsor
University of California, San Francisco
ID
NCT00508963
Study Type
Expanded Access
Last Updated
Contact us about this trial